Lannett gets OK for generic anti-obesity drug

PHILADELPHIA — Lannett has received approval from the Food and Drug Administration to market its version of an anti-obesity drug.

The FDA approved Lannett's abbreviated new drug application for diethylpropion hydrochloride extended-release tablets in the 75-mg strength. The company expects to begin shipping the product immediately.

“This approval fills out our portfolio of diethylpropion HCl products and adds to our growing portfolio of anti-obesity medications,” Lannett president and CEO Arthur Bedrosian said. “Since June 24, we have received five product approvals, the most in a four-month period in the company’s history, and a significant achievement for our team. Our pipeline remains deep, with a number of ANDAs currently pending at the FDA, several of which we expect to be approved over the next couple of quarters.”

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.